Globus Medical price target raised to $100 from $93 at Barclays
The Fly

Globus Medical price target raised to $100 from $93 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $100 from $93 and keeps an Overweight rating on the shares. The company is on track to return to mid-to-high single-digit sales growth and mid-30’s EBITDA margins, the analyst tells investors in a research note. The firm views Globus Medical’s earnings beat as “impressive” on strong sales and accelerating cost synergies.

Don't Miss out on Research Tools:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App